A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
Status:
Withdrawn
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and tolerability of two active doses of
RGN-352 (thymosin beta 4, Tβ4, Injectable Solution) in patients with acute myocardial
infarction receiving percutaneous coronary intervention angioplasty with or without stent
placement. Approximately 75 subjects will be randomized to receive one of two RGN-352 doses
of 1200 mg, or 450 mg, or placebo, administered iv by iv push daily for the first 3
consecutive days and weekly for 4 more weeks.